Industry News

• FDA's Black Box Warning addressed by Genelex's PlavitestT  The FDA added a new black box warning to Plavix, pointing out the importance of individual patient genetics in determining the effectiveness of Plavix treatment. The relabeling is in response to clinical research demonstrating that one-third of patients are in varying degrees of treatment failure.
  Genelex Corporation March 12, 2010  
• Pfizer discontinues a Phase 3 study of figitumumab  Pfizer announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced NSCLC.
  Pfizer Inc. March 11, 2010  
• Two Phase 3 trials of sunitinib did not meet the primary endpoint  Pfizer announced that two Phase 3 studies of Sutent(R) (sunitinib malate) in advanced breast cancer did not meet their primary endpoints.
  Pfizer Inc. March 11, 2010  
• Cardiac Science announces Q4 and full year 2009 results  Revenue for the fourth quarter of 2009 was $42.2 million, down 17% from the fourth quarter of 2008, but up 8% sequentially from the third quarter of 2009. Revenue for 2009 was $156.8 million, down 24% from 2008.
  Cardiac Science Corporation March 11, 2010  
• Abbott seeks FDA approval of a new six-month 45-mg formulation of Lupron(R) Depot  The U.S. Food and Drug Administration(FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron(R) Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.
  Abbott March 11, 2010  
• Cordis unveils next generation CoCr coronary stent  Cordis Corporation announced the European launch of its next generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent system, which improves upon the ground-breaking PRESILLION(TM), features important technological advances.
  Johnson & Johnson March 11, 2010  
• A. Bruce Montgomery, M.D., joins ZymoGenetics board of directors  ZymoGenetics announced that A. Bruce Montgomery, M.D., was named to the company's Board of Directors. Dr. Montgomery serves as Senior Vice President and Head of Respiratory Therapeutics at Gilead Sciences, and previously founded Corus Pharma.
  ZymoGenetics, Inc. March 11, 2010  
• Seattle Genetics expands antibody-drug conjugate patent Portfolio  Seattle Genetics announced that the U.S. PTO has issued a patent related to its antibody-drug conjugate ADC technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics' ADC programs, most notably brentuximab vedotin.
  Seattle Genetics, Inc. March 11, 2010  
• Dr. Francis S. Collins receives Albany Medical Center Prize  NIH Director Francis S. Collins, M.D., Ph.D. has been named a recipient of the Albany Medical Center Prize in Medicine and Biomedical Research for his leading role in mapping the human genome.
  National Institutes of Health March 10, 2010  
• CombiMatrix Corporation reports fourth quarter 2009 financial results  Revenues for the fourth quarter of 2009 were $1.1 million versus $970,000 for the third quarter of 2009 and $1.2 million in the fourth quarter of 2008.
  CombiMatrix Corporation March 10, 2010  

   (next 10 articles)